Applied Genetic Technologies (AGTC) Reaches $4.75 After 7.00% Up Move; J Goldman & Company LP Has Increased Its Esperion Therapeutics Ne (Call) (ESPR) Holding

May 1, 2018 - By Ellis Scott

Applied Genetic Technologies Corporation (NASDAQ:AGTC) Logo

The stock of Applied Genetic Technologies Corporation (NASDAQ:AGTC) is a huge mover today! The stock increased 3.83% or $0.18 during the last trading session, reaching $4.75. About 53,156 shares traded. Applied Genetic Technologies Corporation (NASDAQ:AGTC) has declined 39.42% since May 1, 2017 and is downtrending. It has underperformed by 50.97% the S&P500.The move comes after 5 months positive chart setup for the $86.00 million company. It was reported on May, 1 by Barchart.com. We have $5.08 PT which if reached, will make NASDAQ:AGTC worth $6.02M more.

J Goldman & Company Lp increased Esperion Therapeutics Inc Ne (Call) (ESPR) stake by 375% reported in 2017Q4 SEC filing. J Goldman & Company Lp acquired 195,000 shares as Esperion Therapeutics Inc Ne (Call) (ESPR)’s stock rose 22.41%. The J Goldman & Company Lp holds 247,000 shares with $16.26M value, up from 52,000 last quarter. Esperion Therapeutics Inc Ne (Call) now has $1.88 billion valuation. The stock increased 0.41% or $0.29 during the last trading session, reaching $70.3. About 323,741 shares traded. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has risen 89.86% since May 1, 2017 and is uptrending. It has outperformed by 78.31% the S&P500.

Investors sentiment decreased to 1.33 in 2017 Q4. Its down 0.34, from 1.67 in 2017Q3. It is negative, as 19 investors sold ESPR shares while 39 reduced holdings. 33 funds opened positions while 44 raised stakes. 22.69 million shares or 0.18% less from 22.73 million shares in 2017Q3 were reported. Keybank National Association Oh invested in 4,991 shares. Bb Biotech Ag invested in 4.38% or 2.36 million shares. Dimensional Fund Advsr Lp holds 0% or 86,676 shares. 9,360 are owned by State Board Of Administration Of Florida Retirement System. Cim Investment Mangement Inc holds 4,294 shares. Teacher Retirement System Of Texas reported 0% stake. Ameritas Investment Partners Inc holds 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR) or 1,310 shares. Voya Management Limited Liability Corp holds 0% or 7,673 shares in its portfolio. Vanguard reported 0% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR). New York-based Bamco Incorporated New York has invested 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). California Pub Employees Retirement Sys invested in 0% or 48,858 shares. Swiss Retail Bank has invested 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Natixis owns 0.01% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 10,077 shares. Ontario Teachers Pension Plan Board holds 0.02% in Esperion Therapeutics, Inc. (NASDAQ:ESPR) or 24,832 shares. J Goldman LP owns 14,577 shares.

Among 18 analysts covering Esperion Therapeutics (NASDAQ:ESPR), 10 have Buy rating, 0 Sell and 8 Hold. Therefore 56% are positive. Esperion Therapeutics had 62 analyst reports since July 28, 2015 according to SRatingsIntel. The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) has “Buy” rating given on Wednesday, June 29 by Lake Street. As per Monday, January 15, the company rating was maintained by Stifel Nicolaus. RBC Capital Markets downgraded the shares of ESPR in report on Wednesday, June 29 to “Sector Perform” rating. Needham maintained it with “Buy” rating and $25 target in Thursday, June 30 report. Deutsche Bank maintained the stock with “Buy” rating in Wednesday, August 9 report. The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) has “Buy” rating given on Monday, June 26 by Stifel Nicolaus. The rating was downgraded by Barclays Capital to “Equal-Weight” on Wednesday, June 29. JMP Securities maintained it with “Market Outperform” rating and $67 target in Wednesday, March 9 report. Chardan Capital Markets maintained Esperion Therapeutics, Inc. (NASDAQ:ESPR) rating on Friday, February 26. Chardan Capital Markets has “Neutral” rating and $13 target. The rating was upgraded by Citigroup on Tuesday, February 28 to “Buy”.

J Goldman & Company Lp decreased Berry Global Group Inc (NYSE:BERY) stake by 74,922 shares to 139,878 valued at $8.21 million in 2017Q4. It also reduced Spdr S&P 500 Etf Tr (SPY) stake by 123,320 shares and now owns 102,880 shares. Ishares Tr (IYR) was reduced too.

Among 10 analysts covering Applied Genetic (NASDAQ:AGTC), 7 have Buy rating, 0 Sell and 3 Hold. Therefore 70% are positive. Applied Genetic has $29 highest and $7 lowest target. $15.14’s average target is 218.74% above currents $4.75 stock price. Applied Genetic had 23 analyst reports since July 22, 2015 according to SRatingsIntel. BMO Capital Markets maintained Applied Genetic Technologies Corporation (NASDAQ:AGTC) rating on Thursday, September 14. BMO Capital Markets has “Outperform” rating and $7 target. On Tuesday, September 13 the stock rating was downgraded by Cantor Fitzgerald to “Hold”. The firm has “Buy” rating given on Wednesday, November 9 by TH Capital. The stock has “Buy” rating by Chardan Capital Markets on Wednesday, July 22. As per Tuesday, September 13, the company rating was downgraded by Janney Capital. On Tuesday, September 13 the stock rating was downgraded by Roth Capital to “Neutral”. Stifel Nicolaus maintained the shares of AGTC in report on Tuesday, February 9 with “Buy” rating. The rating was maintained by BMO Capital Markets with “Outperform” on Tuesday, September 13. As per Thursday, August 10, the company rating was maintained by H.C. Wainwright. TH Capital downgraded the shares of AGTC in report on Tuesday, September 13 to “Neutral” rating.

Analysts await Applied Genetic Technologies Corporation (NASDAQ:AGTC) to report earnings on May, 9. They expect $-0.25 earnings per share, down 400.00% or $0.20 from last year’s $-0.05 per share. After $-0.29 actual earnings per share reported by Applied Genetic Technologies Corporation for the previous quarter, Wall Street now forecasts -13.79% EPS growth.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>